Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 824304, 8 pages
http://dx.doi.org/10.1155/2015/824304
Research Article

Polymorphisms in C-Reactive Protein and Glypican-5 Are Associated with Lung Cancer Risk and Gartrokine-1 Influences Cisplatin-Based Chemotherapy Response in a Chinese Han Population

1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of School of Medicine of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
2National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an 710069, China
3School of Pharmacy, Faculty of Health Science, University of Tasmania, Hobart, TAS 7001, Australia

Received 21 August 2014; Revised 24 December 2014; Accepted 15 January 2015

Academic Editor: Varodom Charoensawan

Copyright © 2015 Shuo Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Yang, D. M. Parkin, L. D. Li, Y. D. Chen, and F. Bray, “Estimation and projection of the national profile of cancer mortality in China: 1991–2005,” British Journal of Cancer, vol. 90, no. 11, pp. 2157–2166, 2004. View at Google Scholar · View at Scopus
  2. J. She, P. Yang, Q. Y. Hong, and C. X. Bai, “Lung cancer in China: challenges and interventions,” Chest, vol. 143, no. 4, pp. 1117–1126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. de Groot and R. F. Munden, “Lung cancer epidemiology, risk factors, and prevention,” Radiologic Clinics of North America, vol. 50, no. 5, pp. 863–876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Hills and P. M. Lansdorp, “Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies,” Annals of the New York Academy of Sciences, vol. 1176, pp. 178–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. C. Seng and C. K. Seng, “The success of the genome-wide association approach: a brief story of a long struggle,” European Journal of Human Genetics, vol. 16, no. 5, pp. 554–564, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. F. Li and P. Yang, “GPC5 gene and its related pathways in lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 2–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Zhou, J. Liu, Z.-M. Wang, and T. Xi, “C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis,” PLoS ONE, vol. 7, no. 8, Article ID e43075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Rafnar, P. Sulem, S. Besenbacher et al., “Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk,” Cancer Research, vol. 71, no. 4, pp. 1356–1361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Broderick, Y. F. Wang, J. Vijayakrishnan et al., “Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study,” Cancer Research, vol. 69, no. 16, pp. 6633–6641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Gu, X. Q. Dong, X. Z. Zhang et al., “Strong association between two polymorphisms on 15q25.1 and lung cancer risk: a meta-analysis,” PLoS ONE, vol. 7, no. 6, Article ID e37970, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. W. Lee, Y. M. Park, S. J. Lee et al., “Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma,” Clinical Cancer Research, vol. 19, no. 21, pp. 5879–5889, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Chen, L. Fu, L.-Y. Zhang, D. L. Kwong, L. Yan, and X.-Y. Guan, “Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma,” Chinese Journal of Cancer, vol. 31, no. 5, pp. 215–222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. J. L. Ramirez, R. Rosell, M. Taron et al., “14-3-3σ methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9105–9112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. K. Thomas, A. C. Baker, R. M. DeBiasi et al., “High-throughput oncogene mutation profiling in human cancer,” Nature Genetics, vol. 39, no. 3, pp. 347–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gabriel, L. Ziaugra, and D. Tabbaa, “SNP genotyping using the sequenom MassARRAY iPLEX platform,” in Current Protocals in Human Genetics, vol. 1, chapter 2, unit 2.12, 2009. View at Google Scholar
  18. C. Adamec, “Example of the use of the nonparametric test. Test X2 for comparison of 2 independent examples,” Ceskoslovenská Zdravotnictví, vol. 12, pp. 613–619, 1964. View at Google Scholar
  19. X. Solé, E. Guinó, J. Valls, R. Iniesta, and V. Moreno, “SNPStats: a web tool for the analysis of association studies,” Bioinformatics, vol. 22, no. 15, pp. 1928–1929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Bland and D. G. Altman, “Statistics notes. The odds ratio,” The British Medical Journal, vol. 320, no. 7247, p. 1468, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Bolayirli, H. Turna, T. Orhanoglu, R. Ozaras, M. Ilhan, and M. Özgüroglu, “C-reactive protein as an acute phase protein in cancer patients,” Medical Oncology, vol. 24, no. 3, pp. 338–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Heikkilä, S. Ebrahim, and D. A. Lawlor, “A systematic review of the association between circulating concentrations of C reactive protein and cancer,” Journal of Epidemiology and Community Health, vol. 61, no. 9, pp. 824–832, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. A. Hefler, N. Concin, G. Hofstetter et al., “Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer,” Clinical Cancer Research, vol. 14, no. 3, pp. 710–714, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. M. Crozier, R. F. McKee, C. S. McArdle et al., “Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer,” The British Journal of Surgery, vol. 94, no. 8, pp. 1028–1032, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. G. W. A. Lamb, D. C. McMillan, S. Ramsey, and M. Aitchison, “The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer,” The British Journal of Cancer, vol. 94, no. 6, pp. 781–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. P. I. Karakiewicz, G. C. Hutterer, Q.-D. Trinh et al., “C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality—a European study of 313 patients,” Cancer, vol. 110, no. 6, pp. 1241–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Hashimoto, Y. Ikeda, D. Korenaga et al., “The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma,” Cancer, vol. 103, no. 9, pp. 1856–1864, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Gockel, K. Dirksen, C. M. Messow, and T. Junginger, “Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3746–3750, 2006. View at Google Scholar · View at Scopus
  29. K. H. Allin and B. G. Nordestgaard, “Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 48, no. 4, pp. 155–170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Xu, M. L. Zhu, Y. G. Du et al., “Serum C-reactive protein and risk of lung cancer: a case-control study,” Medical Oncology, vol. 30, no. 1, article 319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. F. Li, C.-C. Sheu, Y. Q. Ye et al., “Genetic variants and risk of lung cancer in never smokers: a genome-wide association study,” The Lancet Oncology, vol. 11, no. 4, pp. 321–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. T. Landi, N. Chatterjee, N. E. Caporaso et al., “GPC5 rs2352028 variant and risk of lung cancer in never smokers,” The Lancet Oncology, vol. 11, no. 8, pp. 714–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Zheng, M. Kan, L. Yu et al., “GPC5 rs2352028 polymorphism and risk of lung cancer in Han Chinese,” Cancer Investigation, vol. 30, no. 1, pp. 13–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Yoon, Y. J. Choi, W. S. Choi et al., “GKN1-miR-185-DNMT1 axis suppresses gastric carcinogenesis through regulation of epigenetic alteration and cell cycle,” Clinical Cancer Research, vol. 19, no. 17, pp. 4599–4610, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. F. B. Fahlbusch, M. Ruebner, H. Huebner et al., “The tumor suppressor gastrokine-1 is expressed in placenta and contributes to the regulation of trophoblast migration,” Placenta, vol. 34, no. 11, pp. 1027–1035, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. T. V. Perneger, “What's wrong with Bonferroni adjustments,” The British Medical Journal, vol. 316, no. 7139, pp. 1236–1238, 1998. View at Publisher · View at Google Scholar · View at Scopus